The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue to witness sequencer throughput expansion with systems like the Illumina ...
Ultima Genomics, Inc., a developer of ultra-high-throughput sequencing systems, continues its mission to enable sequencing at scale with the unveiling of the UG200 Series and next generation Solaris 2 ...
Microsatellite instability (MSI) serves as an important therapeutic and prognostic marker. Immunohistochemistry (IHC) and polymerase chain reaction (PCR) have long been regarded as the “gold standard” ...
The non-coding genome, once dismissed as "junk DNA", is now recognized as a fundamental regulator of gene expression and a key player in understanding complex diseases. Following the landmark ...
Natera NTRA announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay designed to improve the detection and diagnosis of rare genetic diseases. The core ...
Metagenomic next-generation sequencing (mNGS) offers sensitive and rapid pathogen detection and has the added advantage of analyzing chromosomal copy number variations (CNVs) of the host in the same ...
Key challenges to developing "trans-tumor" targeted therapies are outlined in an editorial in the New England Journal of Medicine published Thursday by Fabrice André, head of the predictive biomarkers ...
Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan–Treated Human Epidermal Growth Factor Receptor 2–Positive ...
Located on the Buffalo Niagara Medical Campus and the first next-generation sequencing service provider in the region, UB's Genomics and Bioinformatics Core Facility provides high-quality services ...
Patients with classic NF1 including the presence of cutaneous neurofibromas or Lisch nodules, as no genetic heterogeneity demonstrated so far associated with this phenotype. The NF1-only by NGS ...
NTRA launches Zenith genomics, a whole genome sequencing assay with MyOme to improve rare disease detection. NTRA will distribute the assay nationwide using its EMR integrations, support systems and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results